Clinical Trial Update: A Study to Learn How Safe the Study Treatment BAY94-9027 is and How it Affects the Body in Previously Treated Children Aged 7 to Less Than 12 Years With Severe Hemophilia A, a Genetic Bleeding Disorder That is Caused by the Lack of a Protein Called Clotting Factor 8 (FVIII) in the Blood [Phase 3]

View source ↗

Summary

Phase 3 trial assessing the safety and pharmacodynamic effects of BAY94-9027 in previously treated children aged 7 to less than 12 with severe Hemophilia A; the…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• BAY94-9027

Snippet

Sponsor: Bayer | Conditions: Treatment of Bleeding, Prophylaxis of Bleeding | Phase 3 | Status: COMPLETED | Results posted: 2025-07-24